Infant and Children's Tylenol Recall

In September 2009 

Some infants' and children's Tylenol were recalled

Here is the article:
Click here to go to the article

For more on the recalled list dating back from 2007-2009 check this site out Here

If you want to read more on the Recall and how to determine whether the medicine you have needs to be pulled off your medicine shelf then click here and read the last article that was posted.

Thu, Sep 24, 2009 (Reuters) - Johnson & Johnson said on Thursday it is recalling some lots of infants' and children's Tylenol because of a possible bacterial contamination of the popular pain and fever treatment.

Tylenol products being recalled were manufactured between April and June 2008, the diversified health care giant said.

The company identified 21 varieties of the products, which come in various flavors and forms, and 57 different lot numbers, affected by the recall..

The company said it has contacted wholesalers and retailers about the recall, which affects only the United States. It was not immediately clear how widely distributed the 57 affected lots were within the United States.

In a letter dated September 18, J&J unit McNeil Consumer Healthcare said that after consulting with the U.S. Food and Drug Administration, it initiated the voluntary recall as a precaution.

The company said that one of the inactive ingredients did not meet internal testing requirements and Burkholderia cepacia, or B. cepacia, bacteria were detected in a portion of raw material that was not used in the finished product.

"However, it was decided, as a precaution, to recall all product that utilized any of the raw material manufactured at the same time as the raw material that tested positive for the bacteria," the letter said, emphasizing that no bacteria were found in the finished product, which met all specifications.

J&J said the likelihood of a serious medical problem arising from the recalled product was remote.

"The FDA is working closely with the company to monitor this recall," agency spokeswoman Sandy Walsh said.

"There are no adverse events reported by patients using this product," she added.

Health consequences of B. cepacia infections could be severe in high-risk patients, such as those with underlying pulmonary disease, cystic fibrosis or compromised immune systems.